MOBERG DERMA AND MEDA EXTEND LICENSE AGREEMENT

MOBERG DERMA AND MEDA EXTEND LICENSE AGREEMENT

Moberg Derma AB (publ.) and Meda have entered into an additional license
agreement for Nalox™ - Moberg Derma’s patented product for the treatment
of discolored and damaged nails caused by nail fungus (onychomycosis) or
nail psoriasis. The agreement extends Meda's rights to market and sell
Nalox™ to Russia, Turkey and several countries in Eastern Europe. Moberg
Derma assumes production and supply responsibility.

Meda launched Nalox™ in Scandinavia in late 2010. Rapidly after the
launch Nalox™ became market leader and has in 2011 strengthened its
leading position in Scandinavia. In September, an agreement was signed
that gave Meda exclusive rights to market and sell Nalox™ in several
major markets in Europe, including Germany, France, Spain and the UK.
Launch is scheduled to start during the first half of 2012.

The new agreement encompasses several major countries, including Russia,
Turkey and Poland, totaling approximately 300 million inhabitants. In
total, Meda’s rights to Nalox™ comprise a total of 22 countries,
representing some 550 million inhabitants.

As compensation for the exclusivity rights, Meda has agreed to pay a
total of SEK 18 million, with SEK 7.5 million at signing of the contract
and the remaining SEK 11.5 million in future milestone payments. In
addition, compensation will be paid for delivered products.

“Our partnership with Meda OTC has been a great success and we are
delighted that Meda expands its commitment to Nalox™ to additional
markets. Since we now have established partnerships for Nalox™ in most
large markets, we have a solid base to reach our financial goal of
positive cash flow and operating profit in 2013. The upfront payment of
this agreement also contributes to that we will deliver a positive
result for the current quarter”, says Peter Wolpert, President and CEO
of Moberg Derma.

About this information
Moberg Derma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication on at 14:00 pm (CET) on
November 30th, 2011.

For further information, please contact:
Peter Wolpert, President and CEO
Telephone: +46 8 522 307 00
Mobile: +46 735 71 35
E-mail: peter.wolpert@mobergderma.se (peter.wolpert@mobergderma.se)

Magnus Persson, IR
Mobile: +46 73-355 26 01
E-mail: magnus.persson@mobergderma.se (magnus.persson@mobergderma.se)